返回 A A A Font Size Receive E-mail Alerts Press Releases

FireMagic™ 3D Gains CFDA Approval

[2017-05-10] 

Shanghai, China – On May 8, Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") obtained a registration certificate from China Food and Drug Administration ("CFDA") for its in-house developed FireMagic™ 3D Ablation Catheter ("FireMagic™ 3D"). The device is designed for cardiac electrophysiological mapping. Combined with radio frequency ablation device, FireMagic™ 3D is indicated for use in treating ECG proven arrhythmia with definite clinical symptoms, including AVRT and AVNRT.
 
FireMagic™ 3D has a high-torque shaft with a deflectable curve section. The tip deflection is controlled at the proximal end by a handle. The high-torque shaft also allows the plane of the curved tip to be rotated to facilitate accurate positioning of the catheter tip at the desired site. When used with Columbus™ 3D EP Navigation System ("Columbus™"), it provides precise location of the catheter curve in the body. FireMagic™ 3D is a unidirectional catheter with four specifications of different curved shapes to meet patients' requirements.
 
The tip electrode of FireMagic™ 3D is equipped with a magnetic oriented sensor to show the location of the catheter tip, and some specifications have an additional magnetic oriented sensor in the proximal end of the curve section to collect the coordinate data of the curve section. When used with Columbus™, it shows the real-time image of the catheter end curve, guiding physicians to do radiofrequency ablation, and meanwhile reducing X-ray exposure to physicians.
 
President of MicroPort® EP Yiyong Sun said: "The CFDA approval of FireMagic™ 3D signifies a major step forward for MicroPort® EP to provide a complete electrophysiological solution for arrhythmia patients with combinations of active and passive devices and equipment."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Hosts the Fifth Science and Technology Conference
[Next]:The Article of "Experience with the Columbus™ 3D EP Navigation System in the Dominican Republic" Published in Cardiac Rhythm News